Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

This article has been updated


We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19 leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Detection and characterization of B cell lymphoblastic leukemia expressing CAR19 in a patient treated with CTL019 therapy.
Fig. 2: Ectopic CAR19 expression on B-ALL cells masks CD19 and creates CTL019-resistant leukemia.

Data availability

All requests for raw and analyzed data and materials are promptly reviewed by the University of Pennsylvania Center for Innovation to see whether the request is subject to any intellectual property or confidentiality obligations. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. All raw and analyzed sequencing data can be found at the NCBI Sequence Read Archive (accession number: SRP155722; analyses of lentiviral integration sites, RNA sequencing and DNA sequencing of genes potentially associated with CD19 relapse) and Adaptive Biotechnologies’ immuneACCESS database (

Change history

  • 23 October 2018

    In the original version of the article, Jun Xu was missing affiliation number 11, indicating an equal contribution, despite being included as an equal contributor in the full list of affiliations. Affiliation number 11 has been added to Jun Xu.


  1. 1.

    Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Sotillo, E. et al. Cancer Discov. 5, 1282–1295 (2015).

    CAS  Article  Google Scholar 

  4. 4.

    Gardner, R. et al. Blood (2016).

    CAS  Article  Google Scholar 

  5. 5.

    Ruella, M. & Maus, M. V. Comput. Struct. Biotechnol. J. 14, 357–362 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Ruella, M. et al. J. Clin. Invest. 126, 3814–3826 (2016).

    Article  Google Scholar 

  7. 7.

    Mueller, K. T. et al. Blood 128, 220 (2016).

    Google Scholar 

  8. 8.

    Marcucci, K. T. et al. Mol. Ther. 26, 269–279 (2018).

    CAS  Article  Google Scholar 

  9. 9.

    Meyerson, H. J. et al. Am. J. Clin. Pathol. 137, 39–50 (2012).

    Article  Google Scholar 

  10. 10.

    Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. Cell 92, 735–745 (1998).

    CAS  Article  Google Scholar 

  11. 11.

    van Zelm, M. C. et al. J. Clin. Invest. 120, 1265–1274 (2010).

    Article  Google Scholar 

  12. 12.

    Friederike Braig, A. B. Blood (2016).

    Article  Google Scholar 

  13. 13.

    Fry, T. J. et al. Nat. Med. 24, 20 (2018).

    CAS  Article  Google Scholar 

  14. 14.

    Ruella, M. et al. Blood 130, 807 (2017).

    Google Scholar 

  15. 15.

    Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Clin. Cancer Res. 8, 995–1002 (2002).

    CAS  PubMed  Google Scholar 

  16. 16.

    Xiao, X., Ho, M., Zhu, Z., Pastan, I. & Dimitrov, D. S. mAbs 1, 297–303 (2009).

  17. 17.

    Haso, W. et al. Blood 121, 1165–1174 (2013).

    CAS  Article  Google Scholar 

  18. 18.

    Grupp, S. A. et al. N. Engl. J. Med. 368, 1509–1518 (2013).

    CAS  Article  Google Scholar 

  19. 19.

    Maude, S. L. et al. N. Engl. J. Med. 371, 1507–1517 (2014).

    Article  Google Scholar 

  20. 20.

    Milone, M. C. et al. Mol. Ther. 17, 1453–1464 (2009).

    CAS  Article  Google Scholar 

  21. 21.

    Ruella, M. et al. Clin. Cancer Res. 22, 2684–2696 (2016).

    CAS  Article  Google Scholar 

  22. 22.

    Zhang, G., Gurtu, V. & Kain, S. R. Biochem. Biophys. Res. Commun. 227, 707–711 (1996).

    CAS  Article  Google Scholar 

  23. 23.

    Tedder, T. F. & Isaacs, C. M. J. Immunol. 143, 712–717 (1989).

    CAS  PubMed  Google Scholar 

  24. 24.

    Heinz, N. et al. Hum. Gene Ther. 22, 166–176 (2011).

    CAS  Article  Google Scholar 

  25. 25.

    Jena, B. et al. PLoS ONE 8, e57838 (2013).

    CAS  Article  Google Scholar 

  26. 26.

    Sherman, E. et al. Mol. Ther. Methods Clin. Dev. 4, 39–49 (2016).

    Article  Google Scholar 

  27. 27.

    Berry, C. C. et al. Bioinformatics 28, 755–762 (2012).

    CAS  Article  Google Scholar 

  28. 28.

    Swennenhuis, J. F., Reumers, J., Thys, K., Aerssens, J. & Terstappen, L. W. Genome Med. 5, 106 (2013).

    Article  Google Scholar 

  29. 29.

    Li, H. & Durbin, R. Bioinformatics 25, 1754–1760 (2009).

    CAS  Article  Google Scholar 

  30. 30.

    McKenna, A. et al. Genome Res. 20, 1297–1303 (2010).

    CAS  Article  Google Scholar 

  31. 31.

    DePristo, M. A. et al. Nat. Genet. 43, 491–498 (2011).

    CAS  Article  Google Scholar 

  32. 32.

    Sherry, S. T. et al. Nucleic Acids Res. 29, 308–311 (2001).

    CAS  Article  Google Scholar 

  33. 33.

    Forbes, S. A. et al. Nucleic Acids Res. 43, D805–D811 (2015).

    CAS  Article  Google Scholar 

  34. 34.

    Kalos, M. et al. Sci. Transl. Med. 3, 95ra73 (2011).

    CAS  Article  Google Scholar 

  35. 35.

    Barrett, D. M. et al. Blood 118, e112–e117 (2011).

    CAS  Article  Google Scholar 

  36. 36.

    Imai, C. et al. Leukemia 18, 676–684 (2004).

    CAS  Article  Google Scholar 

Download references


The authors would like to thank the staff in the Product Development and Correlative Sciences laboratory for helpful discussions and analytical support, staff in Clinical Cell and Vaccine Production Facility for manufacturing and analytical support, and staff in the Stem Cell and Xenograft Facility for animal support (University of Pennsylvania, Philadelphia, PA). The authors would like to thank E. Sotillo and A. Thomas-Tikhonenko (Children’s Hospital of Philadelphia, PA) for providing the CD19 CRISPR–Cas9 knock-out NALM-6 cells and B. Jena and L. Cooper (MD Anderson Cancer Center, Houston, TX) for providing the Alexa-Fluor-647-conjugated anti-idiotype antibody. The chimeric antigen receptor used in this study was obtained under a Material transfer agreement (MTA) from Campana and Imai at St. Jude Children’s Research Hospital and was subsequently modified by cloning into a lentiviral vector and expressed with a eukaryotic promoter. This work was supported by grants from the University of Pennsylvania–Novartis Alliance (principal investigator (PI), C.H.J), National Institutes of Health (NIH) 5R01CA120409 (PI, C.H.J), the EMD–Serono Cancer Immunotherapy Clinical Fellowship by the Society for Immunotherapy of Cancer (SITC) (PI, M.R.), the Bristol–Myers Squibb Oncology Fellowship in Clinical Cancer Research by the American Association for Cancer Research (AACR) (PI, M.R.), the Gabrielle’s Angel Foundation (PI, M.R.; PI, D.M.B.; and PI, J.A.F.), the SIES–AIL fellowship by the Italian Society for Experimental Hematology and the Italian Leukemia Association (PI, M.R.), the ASH-Scholar Award (P.I., M.R.), NIH NCI 1K99CA212302-01A1 (PI, M.R.), NIH NCI P01CA214278-01 (PI, C.H.J.) the St. Baldrick’s Foundation Scholar Award (PI, D.M.B.) and NCI T32CA009140 (J.A.F).

Author information




M.R., J.X., D.M.B., T.J.R., S.I.G., S.A.G., C.H.J., S.F.L., and J.J.M formulated the ideas and planned the experiments. M.R., J.X., D.M.B., T.J.R., M.K., O.S., F.N., D.E.A., I.K., J.A.F., J.S., P.R.P, V.G.B., C.L.N., F.D.B. E.J.O., and H.B. performed the experiments, analyzed the data, and contributed to the manuscript. J.X, M.K., and T.J.R. performed the confocal imaging. C.L.N. and F.D.B. performed the lentivirus integration site analysis. S.L.M., D.M.B., and S.A.G. managed Patient #107 in the clinic. M.R., J.J.M, and S.F.L. wrote the manuscript; S.A.G., B.L.L., R.M.Y., J.S., and C.H.J. edited the manuscript. D.M.B., M.R., and O.S. performed the animal experiments. T.J.F provided clinical care and identified CARB recurrence. All the authors reviewed and accepted the contents of the article. M.R., J.X, and D.M.B equally contributed to this manuscript. S.F.L and J.J.M. share senior authorship.

Corresponding authors

Correspondence to Carl H. June or J. Joseph Melenhorst.

Ethics declarations

Competing interests

C.H.J., J.J.M., M.R., J.S., J.A.F., R.M.Y., and S.I.G. work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc. and are inventors of intellectual property (IP) licensed by the University of Pennsylvania to Novartis. C.L.N. has IP in a CART-related patent. B.L.L. is a consultant for CRC Oncology, Cure Genetics, Novartis and a member of the Scientific Advisory Board for Brammer Bio, Incysus, Avectas. B.L.L. is the founder of and has equity in Tmunity Therapeutics and receives Research Funding from Novartis and Tmunity. S.F.L. receives Novartis, Tmunity and Parker Institute for Cancer immunotherapy research funding and has CART-related IP. S.A.G. discloses Novartis research funding and consultancy. E.O. and H.B. are employed by Novartis. All the other authors have no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–11 and Supplementary Tables 1–6

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ruella, M., Xu, J., Barrett, D.M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24, 1499–1503 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing